ACW

ACTINOGEN FPO [ACW]
Actinogen Medical Limited, a biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia. It develops Xanamem, an oral medication and inhibitor of the 11ß-HSD1 enzyme that achieves target engagement in the brain for the treatment of Alzheimer's disease, major depressive disorder, fragile x syndrome, and other neurological diseases. The company was formerly known as Actinogen Limited and changed its name to Actinogen Medical Limited in November 2015. Actinogen Medical Limited was incorporated in 1999 and is based in Sydney, Australia.
Healthcare · ASX Small Cap
$0.0410 +0.0%

Updated 23 Jul 2026 · Signals refresh every scan

Get alerts when ACW triggers a new signal
Free watchlist with daily scans for 2,200+ ASX stocks
Track ACW — Free

Active Signals

Bullish Signals

  • Beating the Small Ords index — relative strength of 1.34, so it's outpacing the pack
  • Critical cash runway (1.6 quarters)
  • Sentiment is mixed — no strong consensus either way
  • The bigger volume days are the up days — volume-weighted momentum is positive (0.47%/day)
  • Low-priced stock risk ($0.040)
  • RBA hiking (-3pts)
  • Calendar: Quarterly 4C in 8d (+3pts)

Risk Signals

  • Below the 200-day average — the long-term trend is still working against it
  • Piotroski F-Score weak (3/9, low-confidence approx)
  • Deeply negative margins (-243%)
  • Not enough chatter to gauge sentiment — defaulting to neutral
Ask Scout AI about ACW
"What's driving ACW today?" "How does ACW compare to peers?" "Key risks for ACW?"
3 free messages/day · Unlimited with Pro

Recent Catalysts

NONE Application for quotation of securities - ACW
NONE Xanamem depression trial published in British J Psychiatry
NONE Notification of buy-back - ACW

Recent ASX Announcements

2026-07-21 Application for quotation of securities - ACW
2026-07-19 Xanamem depression trial published in British J Psychiatry PRICE SENSITIVE
2026-07-13 Notification of buy-back - ACW
2026-07-12 ACW AAIC poster presentation of XanaMIA trial baseline data
2026-07-07 ACW senior management presentation at AAIC & internationally

Key Metrics

$148.7M
Market Cap
3.7M
Avg Volume
0.7x
Vol Ratio
$0.02 — $0.07
52-Week Range
N/A
Short Interest
N/A
Cash Runway
-110.8%
ROE
-243.2%
Profit Margin

CANSLIM Analysis

FactorRatingDetail
CCurrent EPSfailEPS Growth: 0%
AAnnual EarningsfailCAGR: 0%
NNew Highs / Catalystsneutral
SSupply & DemandneutralFloat: 71%
LLeader vs LaggardlaggardRS: -9
IInstitutional SponsorshipweakInst: 2%
MMarket DirectionneutralNeutral

Sector: Healthcare

102 tickers in this sector

View all Healthcare signals →Browse all ASX tickers A–Z →
Related Tickers
PIQ +23.3%SLD -18.1%ADR -17.9%IDT -17.1%VBS -14.3%
Compare:ACW vs PIQACW vs SLDACW vs ADR
Scout Pro — Deeper Analysis for ACW
Try Pro free for 30 days
Share this analysis

Track ACW and 2,200+ ASX stocks

Get free access to Scout's AI-powered dashboard with daily scans, watchlist alerts, and exit management for every ASX small cap.

Open Dashboard — Free Free Screener
No credit card required